Maja Cigrovski Berkovic

Prof. Maja Cigrovski Berkovic

Clinical Hospital Dubrava
+1
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Aivars LejnieksAivars Lejnieks
Aivars Lejnieks
Maja Cigrovski BerkovicMaja Cigrovski Berkovic
Maja Cigrovski Berkovic
Giuseppe DerosaGiuseppe Derosa
Giuseppe Derosa
The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested.

10 May 2016 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
KKK. Khunti
K. Khunti
SAS. Alsifri
S. Alsifri
RAR. Aronson
R. Aronson
Maja Cigrovski BerkovicMaja Cigrovski Berkovic
Maja Cigrovski Berkovic
CEC. Enters‐Weijnen
C. Enters‐Weijnen
OGon behalf of the HAT Investigator Group
on behalf of the HAT Investigator Group
Aims: To determine the global extent of hypoglycaemia experienced by patients with diabetes using insulin, as there is a lack of data on the prevalence of hypoglycaemia in developed and developing countries. Methods: This non‐interventional, multicentre, 6‐month retrospective and 4‐week prospective study using self‐assessment questionnaire and patient diaries included 27 585 patients, aged ≥18 years, with type 1 diabetes ( T1D ; n = 8022) or type 2 diabetes ( T2D ; n = 19 563) treated with insulin for >12 months, at 2004 sites in 24 countries worldwide. The primary endpoint was the proportion of patients experiencing at least one hypoglycaemic event during the observational period. Results: During the prospective period, 83.0% of patients with T1D and 46.5% of patients with T2D reported hypoglycaemia. Rates of any, nocturnal and severe hypoglycaemia were 73.3 [95% confidence interval ( CI ) 72.6–74.0], 11.3 (95% CI 11.0–11.6) and 4.9 (95% CI 4.7–5.1) events/patient‐year for T1D and 19.3 (95% CI 19.1–19.6), 3.7 (95% CI 3.6–3.8) and 2.5 events/patient‐year (95% CI 2.4–2.5) for T2D , respectively. The highest rates of any hypoglycaemia were observed in Latin America for T1D and Russia for T2D . Glycated haemoglobin level was not a significant predictor of hypoglycaemia. Conclusions: We report hypoglycaemia rates in a global population, including those in countries without previous data. Overall hypoglycaemia rates were high, with large variations between geographical regions. Further investigation into these differences may help to optimize therapy and reduce the risk of hypoglycaemia.

1 August 2017 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
KKKamlesh Khunti
Kamlesh Khunti
SASaud Alsifri
Saud Alsifri
RARonnie Aronson
Ronnie Aronson
Maja Cigrovski BerkovicMaja Cigrovski Berkovic
Maja Cigrovski Berkovic
CECatherine Enters-Weijnen
Catherine Enters-Weijnen
ARAmbady Ramachandran
Ambady Ramachandran
Data on the impact of hypoglycaemia on patients' daily lives and diabetes self-management, particularly in developing countries, are lacking. The aim of this study was to assess fear of, and responses to, hypoglycaemia experienced by patients globally. This non-interventional, multicentre, 4-week prospective study using self-assessment questionnaires and patient diaries consisted of 27,585 patients, ≥18years, with type 1 diabetes (n=8022) or type 2 diabetes (n=19,563) treated with insulin for >12months, at 2004 sites in 24 countries worldwide. Increased blood glucose monitoring (69.7%) and seeking medical assistance (62.0%) were the most common responses in the 4weeks following hypoglycaemic events for patients with type 1 diabetes and type 2 diabetes, respectively. Approximately 44% of patients with type 1 diabetes or type 2 diabetes increased calorie intake in response to a hypoglycaemic episode. Following hypoglycaemia, 3.9% (type 1 diabetes) and 6.2% (type 2 diabetes) of patients took leave from work or study. Regional differences in fear of, and responses to, hypoglycaemia were evident - in particular, a lower level of hypoglycaemic fear and utilisation of healthcare resources in Northern Europe and Canada. Hypoglycaemia has a major impact on patients and their behaviour. These global data for the first time reveal regional variations in response to hypoglycaemia and highlight the importance of patient education and management strategies.

12 January 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
DKDoris Ogresta Kordej
Doris Ogresta Kordej
Anna MrzljakAnna Mrzljak
Anna Mrzljak
Maja Cigrovski BerkovicMaja Cigrovski Berkovic
Maja Cigrovski Berkovic
IBInes Bilić-Čurčić
Ines Bilić-Čurčić
SSSanja Stojsavljevic Shapeski
Sanja Stojsavljevic Shapeski
LJLucija Virović Jukić
Lucija Virović Jukić
Non-alcoholic fatty liver disease (NAFLD) is closely related to insulin resistance, type 2 diabetes mellitus and obesity. It is considered a multisystem disease and there is a strong association with cardiovascular disease and arterial hypertension, which interfere with changes in the coagulation system. Coagulation disorders are common in patients with hepatic impairment and are dependent on the degree of liver damage. Through a review of the literature, we consider and discuss possible disorders in the coagulation cascade and fibrinolysis, endothelial dysfunction and platelet abnormalities in patients with NAFLD.

MPMelita Vuksic Polic
Melita Vuksic Polic
Maja MiskulinMaja Miskulin
Maja Miskulin
MSMartina Smolic
Martina Smolic
KKKristina Kralik
Kristina Kralik
Ivan MiskulinIvan Miskulin
Ivan Miskulin
IBInes Bilić-Čurčić
Ines Bilić-Čurčić
Background: It is still debatable whether psoriasis increases cardiovascular risk indirectly since it is associated with metabolic syndrome or is an independent cardiovascular risk factor. The aim of this study was to evaluate psoriasis severity as an independent predictor of insulin resistance (IR) irrespective of the presence of metabolic syndrome (MetS). Methods: This was a case control study including 128 patients stratified into two groups: patients with psoriasis and metabolic syndrome vs. patients with psoriasis and no metabolic syndrome. MetS was diagnosed according to ATP III criteria with homeostatic model assessment of insulin resistance (HOMA-IR), as well as a homeostatic model assessment of beta cell function (HOMA-β) were calculated. Results: Compared to subjects without metabolic syndrome, patients with metabolic syndrome had a significantly higher Psoriasis Area Severity Index (PASI) values (p < 0.001). The strongest correlation was established for HOMA-IR and the PASI index (p < 0.001), even after adjustment for body mass index (BMI) in regression analysis model. In patients without MetS and severe forms of disease, the HOMA-IR and HOMA-β values were significantly higher compared to mild forms of disease (p < 0.001 for all) while in subjects with MetS no difference was established for HOMA-IR or HOMA-β based on disease severity. Conclusions: Psoriasis severity is an independent risk factor of HOMA-IR, the strongest association being present in the non-MetS group, who still had preserved beta cell function suggesting direct promotion of atherosclerosis via insulin resistance depending on the disease severity, but irrespective of the presence of metabolic syndrome.

5 October 2021 in Frontiers in Nutrition
Verified
Journal Article
Open access
Maja Cigrovski BerkovicMaja Cigrovski Berkovic
Maja Cigrovski Berkovic
IBInes Bilic-Curcic
Ines Bilic-Curcic
Anna MrzljakAnna Mrzljak
Anna Mrzljak
VCVjekoslav Cigrovski
Vjekoslav Cigrovski
Along with the increase in obesity and type 2 diabetes, the non-alcoholic fatty liver disease (NAFLD) incidence is escalating, thus becoming a leading cause of liver cirrhosis and a significant burden of liver-related outcomes. Since there is no pharmacotherapy available to address the NAFLD, the most effective solutions seem to be lifestyle changes centered on physical activity. Exercise could mediate its beneficial effects directly on the liver and indirectly via extrahepatic pathways, forming a dose-response relationship with NAFLD in terms of prevalence and disease severity. Health-enhancing physical activity (HEPA) levels are mainly needed to exert beneficial effects in obese subjects, while even a small amount of exercise can be beneficial for lean individuals to prevent NAFLD. This mini-review addresses three major points regarding physical activity and NAFLD: prevention, treatment, and extrahepatic benefits, offering recommendations on type and intensity of exercise in liver disease.